AZD8154

inhaled dual PI3K_,_ kinase inhibitor

Ph. II (3 mg QD) for asthma; withdrawn

from re-opt. of oral PI3K_ inhibitor

Journal of Medicinal Chemistry

AstraZeneca, Gothenburg, SE

7. The AstraZeneca inhaled dual PI3K_,_ inhibitor AZD8154 is long-acting in the lung but has low systemic exposure and is selective, potentially avoiding the known side effects of systemic…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks